🇺🇸 FDA

Intelligence · Patent portfolio

Sarepta Therapeutics Patents

Full USPTO pharma patent portfolio for Sarepta Therapeutics — grant dates, expiration, and drug cross-links.

Patents
102
Expiring ≤24m
0

Quick answer

Sarepta Therapeutics has 102 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Page 2 of 3

  1. US 10344281

    Functionally-modified oligonucleotides and subunits thereof

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10337003

    Compositions for treating muscular dystrophy

    Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10300149

    Compositions for enhancing transport of molecules into cells

    Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10202602

    Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10144762

    Antibacterial antisense oligonucleotide and method

    Expires Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10106796

    Compound and method for treating myotonic dystrophy

    Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10076536

    Oligonucleotide analogues targeting human LMNA

    Expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10066228

    Oligonucleotides for treating expanded repeat diseases

    Expires Mon Aug 30 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10006031

    Antisense composition and method for treating muscle atrophy

    Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9982261

    Antisense antiviral compounds and methods for treating a filovirus infection

    Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9944926

    Induced exon inclusion in spinal muscle atrophy

    Expires Mon Apr 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9920085

    Boronic acid conjugates of oligonucleotide analogues

    Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9862946

    Peptide oligonucleotide conjugates

    Expires Mon Jan 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9790499

    Functionally-modified oligonucleotides and subunits thereof

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9682097

    Oligonucleotide analogues targeting human LMNA

    Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9534220

    Antisense antibacterial method and compound

    Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9506058

    Compositions for treating muscular dystrophy

    Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9499583

    Antibacterial antisense oligonucleotide and method

    Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9487786

    Immunosuppression compound and treatment method

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9469664

    Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups

    Expires Mon Oct 13 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9453225

    Multiple exon skipping compositions for DMD

    Expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9447416

    Multiple exon skipping compositions for DMD

    Expires Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9447417

    Multiple exon skipping compositions for DMD

    Expires Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9434948

    Multiple exon skipping compositions for DMD

    Expires Mon Sep 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9416361

    Splice-region antisense composition and method

    Expires Mon Aug 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9394323

    Antisense antiviral compound and method for treating influenza viral infection

    Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9382536

    Antisense antiviral compounds and methods for treating a filovirus infection

    Expires Mon Jun 30 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9347063

    Oligonucleotide analog and method for treating flavivirus infections

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9278987

    Functionally-modified oligonucleotides and subunits thereof

    Expires Mon Mar 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9249243

    Antibacterial antisense oligonucleotide and method

    Expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9238042

    Antisense modulation of interleukins 17 and 23 signaling

    Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9234198

    Multiple exon skipping compositions for DMD

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9217148

    Exon skipping compositions for treating muscular dystrophy

    Expires Mon Dec 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9161948

    Peptide oligonucleotide conjugates

    Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9066967

    Oligonucleotide analogues targeting human LMNA

    Expires Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9068185

    Antisense modulation of nuclear hormone receptors

    Expires Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8933216

    Immunosuppression compound and treatment method

    Expires Mon Jan 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8906872

    Antisense antiviral compound and method for treating ssRNA viral infection

    Expires Mon Dec 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8895722

    Splice-region antisense composition and method

    Expires Mon Nov 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8877725

    Peptide conjugated, inosine-substituted antisense oligomer compound and method

    Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8871918

    Multiple exon skipping compositions for DMD

    Expires Mon Oct 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8865883

    Multiple exon skipping compositions for DMD

    Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8835402

    Compound and method for treating myotonic dystrophy

    Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8785407

    Antisense antiviral agent and method for treating ssRNA viral infection

    Expires Mon Jul 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8785410

    Antisense composition and method for treating muscle atrophy

    Expires Mon Jul 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8779128

    Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups

    Expires Mon Jul 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8741863

    Compound and method for treating myotonic dystrophy

    Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8703735

    Antisense antiviral compounds and methods for treating a filovirus infection

    Expires Mon Apr 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Sarepta Therapeutics have?

102 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Sarepta Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.